scholarly journals Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition

2014 ◽  
Vol 11 (4) ◽  
pp. 265-271 ◽  
Author(s):  
Ajoy Dias ◽  
Dharamvir Jain
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Kinase Inhibition ◽  
Tyrosine Kinase Inhibition ◽  
New Frontier

scholarly journals Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Blood ◽  
2014 ◽  
Vol 123 (8) ◽  
pp. 1207-1213 ◽  
Author(s):  
Jennifer A. Woyach ◽  
Engin Bojnik ◽  
Amy S. Ruppert ◽  
Matthew R. Stefanovski ◽  
Virginia M. Goettl ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mouse Model ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Genetic Inactivation ◽  
Key Points

Key Points Kinase-functional BTK is important in the development and expansion of CLL. Both targeted genetic inactivation of BTK and inhibition of BTK by ibrutinib inhibit the development of CLL in the TCL1 mouse model.

scholarly journals Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis

2020 ◽  
Vol 130 (9) ◽  
pp. 4759-4770
Author(s):  
Melanie C. Dispenza ◽  
Rebecca A. Krier-Burris ◽  
Krishan D. Chhiba ◽  
Bradley J. Undem ◽  
Piper A. Robida ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Kinase Inhibition ◽  
Tyrosine Kinase Inhibition ◽  
Ige Mediated
Sign in / Sign up

Export Citation Format

Share Document